Be part of the knowledge.™

CME/CE

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.

5771

LikeLikedUnlike

Episodes 166-180 of 877

MinuteCE®
Idiopathic Multicentric Castleman Disease Patient Journey: Optimizing Best Practices to Improve Patient-Centric Outcomes
- Corey Casper, MD, MPH
  Peer
- Sudipto Mukherjee, MD, PhD, MPH
  Peer
- Jovanna De La Pena
  Peer
1.00 credits 9 episodes
Personalized Obesity Management: A Comprehensive Approach
MinuteCE®
Personalized Obesity Management: A Comprehensive Approach
- Donna Ryan, MD
  Peer
- Andreea Ciudin, MD, PhD
  Peer
1.50 program credits
Diagnosing Obesity: Beyond BMI
MinuteCE®
Diagnosing Obesity: Beyond BMI
- Walmir Coutinho, MD
  Peer
- Charles P. Vega, MD
  Peer
1.50 program credits
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
MinuteCE®
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
MinuteCE®
Novel Neoadjuvant and Adjuvant Immunotherapy Strategies for GI Malignancies: The Evidence
- Alan Venook, MD
  Peer
1.25 program credits
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
MinuteCE®
Expert Opinion: Key Insights on GI Malignancies—Integrating NCCN Clinical Practice Guidelines Into Practice
- Sara Lonardi, MD
  Peer
- Aparna R. Parikh, MD
  Peer
- Alan Venook, MD
  Peer
1.25 program credits
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
MinuteCE®
Current Guideline Recommendations for Biomarker-Based Second-Line Treatment of mCRC
- Aparna R. Parikh, MD
  Peer
1.25 program credits
Expert Viewpoint: Optimizing Breast Cancer Treatment
MinuteCE®
Expert Viewpoint: Optimizing Breast Cancer Treatment
- William J. Gradishar, MD
  Peer
- Erica L. Mayer, MD, MPH
  Peer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
MinuteCE®
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
- Sara Lonardi, MD
  Peer
1.25 program credits
Management of HER2-Low MBC Following First-Line Disease Progression
MinuteCE®
Management of HER2-Low MBC Following First-Line Disease Progression
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
MinuteCE®
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
- Peter Schmid, FRCP, MD, PhD
  Peer
1.50 program credits
The Evolving Treatment Landscape for MBC: Emerging Therapies
MinuteCE®
The Evolving Treatment Landscape for MBC: Emerging Therapies
- William J. Gradishar, MD
  Peer
1.50 program credits
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
MinuteCE®
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
- Sara Lonardi, MD
  Peer
1.25 program credits
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
MinuteCE®
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
- Alan Venook, MD
  Peer
1.25 program credits
Management of HR+, HER2- High-Risk EBC
MinuteCE®
Management of HR+, HER2- High-Risk EBC
- Erica L. Mayer, MD, MPH
  Peer
1.50 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended